Literature DB >> 15280776

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

Bluma Brenner1, Jean-Pierre Routy, Yudong Quan, Daniela Moisi, Maureen Oliveira, Dan Turner, Mark A Wainberg.   

Abstract

OBJECTIVE: The authors previous studies documented persistence of multidrug resistance (MDR) acquired in five primary HIV-1 infection (PHI) cases for 1-2 years in the absence of antiretroviral treatment. This study characterizes the evolution of transmitted wild-type (WT) (n = 15), resistant (n = 10), and MDR (n = 6) infections. Long-term persistence of MDR infections (2-7 years), leading to one observed MDR superinfection is documented.
METHODS: Genotypic changes in circulating viral quasi-species were evaluated over 1.5-7 years in patients (n = 31) enrolled in the PHI study. Sequencing of reverse transcriptase and protease regions identified nucleotide substitutions in the viral quasi-species and mutations at sites implicated in resistance to antiretroviral drugs. Phylogenetic and clonal analysis were performed to confirm one observed superinfection.
RESULTS: Patients acquiring WT, drug-resistant and MDR infections showed little quasi-species evolution (> 99.6% homology) for more than 1.5 years, regardless of route of transmission. Transmitted resistance mutations (other than 184V) persisted for 2-7 years. MDR persistence in two PHI cases contrasted with the corresponding rapid reversion of MDR infections to WT in their partners following treatment interruption. One MDR transmission eliciting low-level viremia resulted in clearance of the original MDR infection followed by re-infection with a second heterologous MDR strain from a different partner. Phylogenetic and clonal analysis of source and index partner confirmed the superinfection. Both MDR species showed approximately 13-fold reductions in replication capacity relative to the homologous WT strain isolated from the source partner.
CONCLUSIONS: Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280776     DOI: 10.1097/01.aids.0000131377.28694.04

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  38 in total

1.  What HIV-positive MSM want from sexual risk reduction interventions: findings from a qualitative study.

Authors:  Peter A Vanable; Michael P Carey; Jennifer L Brown; Rae A Littlewood; Rebecca Bostwick; Donald Blair
Journal:  AIDS Behav       Date:  2012-04

Review 2.  Secondary HIV prevention: novel intervention approaches to impact populations most at risk.

Authors:  Jennifer L Brown; Ralph J Diclemente
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.

Authors:  Matt A Price; Carole L Wallis; Shabir Lakhi; Etienne Karita; Anatoli Kamali; Omu Anzala; Eduard J Sanders; Linda-Gail Bekker; Rogers Twesigye; Eric Hunter; Pontiano Kaleebu; Kayitesi Kayitenkore; Susan Allen; Eugene Ruzagira; Mary Mwangome; Gaudensia Mutua; Pauli N Amornkul; Gwynn Stevens; Sergei L K Pond; Malinda Schaefer; Mary A Papathanasopoulos; Wendy Stevens; Jill Gilmour
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

5.  Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  MedGenMed       Date:  2005-07-27

6.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

7.  Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

Authors:  Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

8.  Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Authors:  Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

9.  HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk?

Authors:  Mary S Campbell; Geoffrey S Gottlieb; Stephen E Hawes; David C Nickle; Kim G Wong; Wenjie Deng; Thomas M Lampinen; Nancy B Kiviat; James I Mullins
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  J Int AIDS Soc       Date:  2005-07-27       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.